141 related articles for article (PubMed ID: 9696931)
1. Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benign ovarian tumours.
Athanassiadou P; Petrakakou E; Sakelariou V; Zerva C; Liossi A; Michalas S; Athanassiades P
Eur J Cancer Prev; 1998 Jun; 7(3):225-31. PubMed ID: 9696931
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas. Correlation with clinicopathology and sex steroid receptor status.
Koshiyama M; Konishi I; Mandai M; Komatsu T; Yamamoto S; Nanbu K; Mori T
Virchows Arch; 1995; 425(6):603-9. PubMed ID: 7697217
[TBL] [Abstract][Full Text] [Related]
3. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas.
Diebold J; Baretton G; Felchner M; Meier W; Dopfer K; Schmidt M; Löhrs U
Am J Clin Pathol; 1996 Mar; 105(3):341-9. PubMed ID: 8602616
[TBL] [Abstract][Full Text] [Related]
4. P53, bcl-2, and nm23 expressions in serous ovarian tumors: correlation with the clinical and histopathological parameters.
Arik D; Kulaçoğlu S
Turk Patoloji Derg; 2011 Jan; 27(1):38-45. PubMed ID: 21469425
[TBL] [Abstract][Full Text] [Related]
5. Expression of apoptosis-related proteins in endometriomas and benign and malignant ovarian tumours.
Fauvet R; Poncelet C; Hugol D; Lavaur A; Feldmann G; Daraï E
Virchows Arch; 2003 Jul; 443(1):38-43. PubMed ID: 12756564
[TBL] [Abstract][Full Text] [Related]
6. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
[TBL] [Abstract][Full Text] [Related]
7. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
Skirnisdóttir I; Seidal T; Gerdin E; Sorbe B
Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical bcl-2 expression, p53 overexpression, PR and ER status in endometrial carcinoma and survival outcomes.
Kalogiannidis I; Bobos M; Papanikolaou A; Makedos A; Amplianitis I; Vergote I; Nenopoulou E; Makedos G
Eur J Gynaecol Oncol; 2008; 29(1):19-25. PubMed ID: 18386458
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
10. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
[TBL] [Abstract][Full Text] [Related]
11. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression.
Sivridis E; Giatromanolaki A; Koukourakis M; Anastasiadis P
Virchows Arch; 2001 May; 438(5):470-7. PubMed ID: 11407475
[TBL] [Abstract][Full Text] [Related]
12. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.
Nezhat F; Cohen C; Rahaman J; Gretz H; Cole P; Kalir T
Cancer; 2002 Jun; 94(11):2935-40. PubMed ID: 12115382
[TBL] [Abstract][Full Text] [Related]
13. Estrogen and progesterone receptors in epithelial ovarian tumours.
Glavind K; Grove A
APMIS; 1990 Oct; 98(10):916-20. PubMed ID: 2245010
[TBL] [Abstract][Full Text] [Related]
14. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors.
Lindgren P; Bäckström T; Mählck CG; Ridderheim M; Cajander S
Int J Oncol; 2001 Jul; 19(1):31-8. PubMed ID: 11408919
[TBL] [Abstract][Full Text] [Related]
15. DNA ploidy and MYC DNA amplification in ovarian carcinomas. Correlation with p53 and bcl-2 expression, proliferative activity and prognosis.
Diebold J; Suchy B; Baretton GB; Blasenbreu S; Meier W; Schmidt M; Rabes H; Löhrs U
Virchows Arch; 1996 Nov; 429(4-5):221-7. PubMed ID: 8972757
[TBL] [Abstract][Full Text] [Related]
16. p53 and related proteins in epithelial ovarian cancer.
Sengupta PS; McGown AT; Bajaj V; Blackhall F; Swindell R; Bromley M; Shanks JH; Ward T; Buckley CH; Reynolds K; Slade RJ; Jayson GC
Eur J Cancer; 2000 Dec; 36(18):2317-28. PubMed ID: 11094305
[TBL] [Abstract][Full Text] [Related]
17. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
Wen J; Shi JL; Shen DH; Chen YX; Song QJ
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis in epithelial ovarian tumours Prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax).
de la Torre FJ; García A; Gil-Moreno A; Planaguma J; Reventos J; Ramón y Cajal S; Xercavins J
Eur J Obstet Gynecol Reprod Biol; 2007 Jan; 130(1):121-8. PubMed ID: 16876311
[TBL] [Abstract][Full Text] [Related]
19. Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage.
Muller P; Coates PJ; Nenutil R; Trcka F; Hrstka R; Chovanec J; Brychtova V; Vojtesek B
J Ovarian Res; 2019 Mar; 12(1):30. PubMed ID: 30917858
[TBL] [Abstract][Full Text] [Related]
20. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Sep; 29(9):924-31. PubMed ID: 9744308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
